Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Haruki Kume, Yukio Homma, Nobuo Shinohara, Wataru Obara, Tsunenori Kondo, Go Kimura, Hiroyuki Fujimoto, Norio Nonomura, Fumiya Hongo, Takayuki Sugiyama, Masayuki Takahashi, Hiro-Omi Kanayama, Tomoharu Fukumori, Masatoshi Eto
OBJECTIVES: Perinephric fat invasion (PFI) of renal cell carcinoma (RCC) is known to be associated with adverse pathological features and poor prognosis. We analyzed these associations using a sub-group of the RCC registry of The Cancer Registration Committee of the Japanese Urological Association. METHODS: The study cohort of 2998 non-metastatic cases was retrieved from RCC registry (3648 in total). We compared clinicopathological characteristics of cases with PFI (n = 256) and without PFI (n = 2742), and investigated the impact of PFI on cancer-specific survival using univariate and multivariate analyses...
April 12, 2019: Japanese Journal of Clinical Oncology
Mehran Yusuf, Jeremy Gaskins, Emma Trawick, Paul Tennant, Jeffrey Bumpous, Victor van Berkel, Matthew Fox, Neal Dunlap
OBJECTIVE(S): To identify predictors for receiving adjuvant radiation therapy (RT) and investigate the impact of adjuvant RT on survival for patients with resected primary tracheal carcinoma (PTC). METHODS: The National Cancer database was queried for patients with PTC diagnosed from 2004 to 2014 undergoing resection. Patients who died within 30 days of resection were excluded to minimize immortal time bias. Kaplan-Meier methods, Cox regression modeling and propensity score weighted (PSW) log-rank tests were considered to assess the relationship between adjuvant RT and overall survival (OS)...
April 12, 2019: Japanese Journal of Clinical Oncology
Su-Su Zhang, Jin-Xia Liu, Jing Zhu, Ming-Bing Xiao, Cui-Hua Lu, Run-Zhou Ni, Li-Shuai Qu
BACKGROUND AND AIM: The impact of transarterial chemoembolization (TACE) and preventive antiviral therapy on the occurrence of hepatitis B virus (HBV) reactivation and subsequent hepatitis remains controversial. This meta-analysis aimed to evaluate the effect of TACE and preventive antiviral therapy on the risk of HBV reactivation and subsequent hepatitis. Meanwhile, we explored the role of HBeAg status in HBV reactivation after TACE. METHODS: We performed this meta-analysis with 11 included studies to assess the effect of TACE and preventive antiviral therapy on predicting clinical outcomes in HBV-related hepatocellular carcinoma (HCC)...
April 10, 2019: Japanese Journal of Clinical Oncology
Toshihide Hirai, Yusuke Shinoda, Ryosuke Tateishi, Yoshinari Asaoka, Koji Uchino, Taijiro Wake, Hiroshi Kobayashi, Masachika Ikegami, Ryoko Sawada, Nobuhiko Haga, Kazuhiko Koike, Sakae Tanaka
BACKGROUND: With the improvement in survival of hepatocellular carcinoma patients, extrahepatic metastases have become a more frequent complication. Although pathological fractures or paralysis due to bone metastases deteriorate the quality of life of patients, no treatment guideline for bone metastases has been established. This study aimed to clarify the risk factors for these events and the clinical course of patients with bone metastases. METHODS: Out of 783 hepatocellular carcinoma patients treated in our institution between 2009 and 2016, 76 patients with bone metastases were enrolled...
April 8, 2019: Japanese Journal of Clinical Oncology
Meijin Nakayama, F Christopher Holsinger, Dominique Chevalier, Ryan K Orosco
No abstract text is available yet for this article.
April 8, 2019: Japanese Journal of Clinical Oncology
Ryoko Machii, Kumiko Saika
No abstract text is available yet for this article.
April 3, 2019: Japanese Journal of Clinical Oncology
Yoshihiko Tomita, Satoshi Fukasawa, Nobuo Shinohara, Hiroshi Kitamura, Mototsugu Oya, Masatoshi Eto, Kazunari Tanabe, Mitsuru Saito, Go Kimura, Junji Yonese, Masahiro Yao, Hirotsugu Uemura
BACKGROUND: Nivolumab treatment resulted in superior efficacy and safety versus everolimus treatment in the 2-year follow-up of the CheckMate 025 Phase III study, with consistent results in the global population and the Japanese population. Here, we report the 3-year follow-up in both groups. METHODS: Patients were randomized 1:1 to nivolumab 3 mg/kg intravenously every 2 weeks or everolimus 10 mg orally once daily until progression/intolerable toxicity. The primary endpoint was overall survival (OS)...
April 3, 2019: Japanese Journal of Clinical Oncology
Qing Liu, Wei Luo, Can Zhang, Zhan Liao, Yupeng Liu, Hongbo He
OBJECTIVE: The purpose of this study is to retrospectively analyze the clinical efficacy of free fibula autograft and wrist arthroplasty in the treatment of giant cell tumors (GCT) of distal radius. METHODS: We retrospectively reviewed 26 patients with GCT of distal radius who underwent free autogenous fibula graft and wrist arthroplasty for repairing residual defect after en-block resection. The length of the fibula graft was 8.2 cm (6-10 cm). Postoperative follow-up regularly for an mean of 66...
April 3, 2019: Japanese Journal of Clinical Oncology
Yuehui Zhang, Jia Song, Qili Shi, Xupu Song, Libing Shen, Jingqi Zhou, Jiang Shao
BACKGROUND: Ewing sarcoma is a malignant bone tumor mainly affecting teenagers and young adults. Its main driver mutation, the EWS-FLI1 fusion gene, has been identified more than 20 years ago, whereas its other somatic mutations have been just recently reported. METHODS: In this study, we organized the somatic mutations from 216 Ewing sarcoma cases into 216 individual protein-protein interaction networks by using interactome information. These mutation networks were then classified into five different clusters based on their structural similarities...
March 30, 2019: Japanese Journal of Clinical Oncology
Jieyun Zhang, Zhe Gong, Yiwei Gong, Weijian Guo
BACKGROUND: Surgical resection of patients with resectable Stage IV colorectal cancer (CRC) is regarded as first choice if possible. However, its influence on overall survival (OS) has not been thoroughly explored. In this study, we aimed to construct nomograms to help predict 1-, 3- and 5-year OS rate and colorectal cancer-specific survival (CCSS) rate. METHODS: A total of 2996 cases who underwent primary and metastatic resection were selected in the study from surveillance, epidemiology and end results (SEER) database...
March 29, 2019: Japanese Journal of Clinical Oncology
Kazuhiko Yoshida, Toshio Takagi, Tsunenori Kondo, Hirohito Kobayashi, Junpei Iizuka, Hironori Fukuda, Hiroki Ishihara, Masayoshi Okumi, Hideki Ishida, Kazunari Tanabe
We reviewed the clinical efficacy of axitinib after nivolumab treatment failure in six patients with metastatic renal cell carcinoma (RCC); the patients had received nivolumab treatment following vascular endothelial growth factor receptor (VEGFR) inhibitors. Most had undergone radical nephrectomy; five had clear-cell carcinoma and acquired cystic disease-associated carcinoma. The patients were finally diagnosed with progressive disease during nivolumab treatment. Immediately after nivolumab treatment failure, one patient receiving pazopanib had an adverse event soon after, and subsequently received axitinib, which the others received...
March 29, 2019: Japanese Journal of Clinical Oncology
Hidekazu Hirano, Ken Kato
Systemic treatment of advanced esophageal squamous cell carcinoma (ESCC) mainly consists of cytotoxic agents, aiming to palliate symptoms and prolong survival. Cisplatin and 5-fluorouracil have been considered standard treatment for several decades. Efforts to develop more effective treatment have led to clinical trials testing triplet, irinotecan-based, oxaliplatin-based and paclitaxel-based regimens. Molecular-targeting agents, mainly anti-EGFR inhibitors including gefitinib, panitumumab and nimotuzumab, have been investigated; however, no molecular-targeting agents demonstrate the clinical utility in Phase 3 trials so far...
March 28, 2019: Japanese Journal of Clinical Oncology
Takashi Hatano, Taishi Matsu-Ura, Kei-Ichiro Mori, Hiroyuki Inaba, Katsuhisa Endo, Mayumi Tamari, Shin Egawa
Hyperprogression has recently been recognized as a new pattern of progression in patients undergoing immune checkpoint inhibitor treatment. Here, we report two cases that showed hyperprogression during the initial phase of pembrolizumab treatment for metastatic urothelial carcinoma. The first patient, who received pembrolizumab as a second-line treatment, developed severe respiratory failure due to the rapid progression of lung metastases on the ninth day after the third pembrolizumab treatment. The second patient developed jaundice and hepatic dysfunction due to the progression of a metastatic lymph node of the liver hilum after the first administration of pembrolizumab...
March 28, 2019: Japanese Journal of Clinical Oncology
Kazuhisa Nakashima, Madoka Kimura, Hiroaki Akamatsu, Haruko Daga, Hisao Imai, Tetsuhiko Taira, Ryo Ko, Yasushi Hisamatsu, Kazumi Nishino, Takeya Sugimoto, Yosuke Miyashita, Toshiaki Takahashi
BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC) in patients who have good performance status (PS). However, the efficacy and safety of osimertinib for patients with poor PS is unknown. METHODS: We retrospectively evaluated the efficacy and safety of osimertinib in patients with EGFR T790M mutation-positive NSCLC who had Eastern Cooperative Oncology Group PS scores of 2-4 and who were administered 80 mg of osimertinib once daily between March 2016 and February 2017...
March 28, 2019: Japanese Journal of Clinical Oncology
Junko Matsuoka, Kota Katanoda
No abstract text is available yet for this article.
March 28, 2019: Japanese Journal of Clinical Oncology
Seiji Niho, Yukio Hosomi, Hiroaki Okamoto, Keiji Nihei, Hiroshi Tanaka, Toyoaki Hida, Shigeki Umemura, Koichi Goto, Tetsuo Akimoto, Yuichiro Ohe
OBJECTIVES: We conducted a Phase I/II study of carboplatin, S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients (71 years or older) with unresectable stage III non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients received carboplatin (AUC 3-5) on Day 1 and S-1 (30-40 mg/m2 two times daily) on Days 1-14, every 2 weeks, for up to four cycles, plus concurrent TRT at a total dose of 60 Gy. The primary endpoint for the Phase II study was the 1-year progression-free survival (PFS) rate...
March 27, 2019: Japanese Journal of Clinical Oncology
Ryunosuke Tanabe, Ken-Ichi Kamo, Keisuke Fukui, Shinpei Imori
Information of prefectural cancer incidence in Japan is an important resource to plan an effective regional cancer control program. In order to obtain accurate prefectural cancer incidence, we have to adjust for both of completeness of regional cancer registries and regional dispersion, simultaneously, Then, we developed a hierarchal Bayes model with a completeness adjustment by using the relation between MI ratio (mortality divided by incidence) and proportion of death certificate notified among incidence...
March 19, 2019: Japanese Journal of Clinical Oncology
Tetsuya Ito, Tatsuro Yamaguchi, Tomokazu Wakatsuki, Tsuyoshi Suzuki, Hidetaka Eguchi, Yasushi Okazaki, Gou Yamamoto, Tetsuhiko Tachikawa, Satoru Kawakami, Astushi Sasaki, Kiwamu Akagi, Hideyuki Ishida
The proband was a 62-year-old man with ureter cancer. He had a history of metachronous colorectal and gastric cancer. Immunohistochemical staining showed the absence of both MSH2 and MSH6 proteins in the ureter cancer and other available cancer tissue specimens. Genetic testing was conducted to identify the causative genes of hereditary gastrointestinal cancer syndromes including mismatch repair genes. We detected a germline variant, c.2635-3delC, within the splice acceptor site of exon 16, in the MSH2 gene...
March 18, 2019: Japanese Journal of Clinical Oncology
Toshiyuki Nakai, Yuji Matsumoto, Shinji Sasada, Midori Tanaka, Takaaki Tsuchida, Yuichiro Ohe, Noriko Motoi
BACKGROUND: Malignant pleural mesothelioma (MPM) is rarely an asbestos-related cancer with a poor prognosis that is difficult to distinguish from some benign conditions by using conventional biopsy techniques. The purpose of this study was to evaluate the utility of a novel biopsy technique using a cryoprobe during flex-rigid pleuroscopy for diagnosing MPM. METHODS: Consecutive patients who underwent pleural cryobiopsy during flex-rigid pleuroscopy from June through November 2017 to diagnose the cause of pleural effusion were collected...
March 18, 2019: Japanese Journal of Clinical Oncology
Juan Wang, Yaping Zhao, Qianqian Chen, Peng Zhang, Wei Xie, Jing Feng, Jie Cao
BACKGROUND: An increasing number of pulmonary lesions-particularly, peripheral lung lesions-are identified with current technological advancements. Notably, the yield of traditional bronchoscopy for the diagnosis of peripheral lung lesions is low. This study evaluated the diagnostic value of rapid on-site evaluation (ROSE) during transbronchial biopsy for peripheral lung cancer. METHODS: This study included 641 patients who underwent transbronchial biopsy for suspected lung cancer at the Respiratory Department of Tianjin Medical University General Hospital between January 2012 and December 2016...
March 11, 2019: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"